Modifiable risk factors and effective interventions affecting outcome in the treatment of Hodgkin lymphoma
| Risk factor . | Frequency, % . | Effective interventions . | Reference . |
|---|---|---|---|
| Reduced pulmonary function, major | ∼5-10 | Omit bleomycin | 120, 121 |
| Left ventricular ejection fraction <50% | ∼5-10 | Omit doxorubicin; consider substitution with etoposide | * |
| HIV infection | 1.2† | Vigorous supportive care with appropriate antibiotics and neutrophil growth factors | 16, 17, 20-27 |
| Positive interim PET scan, limited-stage disease | 15-20 | Involved-field or involved-nodal radiation | 99-102 |
| Risk factor . | Frequency, % . | Effective interventions . | Reference . |
|---|---|---|---|
| Reduced pulmonary function, major | ∼5-10 | Omit bleomycin | 120, 121 |
| Left ventricular ejection fraction <50% | ∼5-10 | Omit doxorubicin; consider substitution with etoposide | * |
| HIV infection | 1.2† | Vigorous supportive care with appropriate antibiotics and neutrophil growth factors | 16, 17, 20-27 |
| Positive interim PET scan, limited-stage disease | 15-20 | Involved-field or involved-nodal radiation | 99-102 |